Thread song
Table Of Contents
I. What oxandrolone is origin structure FDA status
II. Structural chemistry what the 2-oxa modification actually means
III. Mechanism of action AR binding genomic effects IGF-1 pathway
IV. Glucocorticoid receptor antagonism the anti-catabolic mechanism
V. Muscle effects what the clinical trials actually show
VI. Bone effects BMD osteoblast stimulation clinical data
VII. FDA approved indications the full clinical evidence base
VIII. Oral bioavailability 17-alpha alkylation why it survives first pass
IX. Hepatotoxicity the liver cost of 17-AA
X. Lipid effects HDL suppression cardiovascular implications
XI. HPTA suppression how significant is it for oxandrolone
XII. Androgenic side effects virilisation hair skin why it is milder
XIII. Oxandrolone vs other oral AAS comparison
XIV. Legal status and scheduling
XV. Verdict
I. What oxandrolone is origin structure FDA status
II. Structural chemistry what the 2-oxa modification actually means
III. Mechanism of action AR binding genomic effects IGF-1 pathway
IV. Glucocorticoid receptor antagonism the anti-catabolic mechanism
V. Muscle effects what the clinical trials actually show
VI. Bone effects BMD osteoblast stimulation clinical data
VII. FDA approved indications the full clinical evidence base
VIII. Oral bioavailability 17-alpha alkylation why it survives first pass
IX. Hepatotoxicity the liver cost of 17-AA
X. Lipid effects HDL suppression cardiovascular implications
XI. HPTA suppression how significant is it for oxandrolone
XII. Androgenic side effects virilisation hair skin why it is milder
XIII. Oxandrolone vs other oral AAS comparison
XIV. Legal status and scheduling
XV. Verdict
I. What Oxandrolone Is
Oxandrolone is a synthetic oral anabolic-androgenic steroid (AAS) firstsynthesised by Raphael Pappo and Christopher J. Jung at Searle Laboratoriesin 1962. It was developed with the explicit goal of producing a compoundwith high anabolic potency and minimal androgenic side effects. Commercially marketed as Anavar (Searle) from 1964. Discontinued by Searlein 1989 following AAS scheduling. Reintroduced by BTG (now Savient) asOxandrin in 1995. Still manufactured by multiple pharmaceutical companies.
Oxandrolone is a synthetic oral anabolic-androgenic steroid (AAS) firstsynthesised by Raphael Pappo and Christopher J. Jung at Searle Laboratoriesin 1962. It was developed with the explicit goal of producing a compoundwith high anabolic potency and minimal androgenic side effects. Commercially marketed as Anavar (Searle) from 1964. Discontinued by Searlein 1989 following AAS scheduling. Reintroduced by BTG (now Savient) asOxandrin in 1995. Still manufactured by multiple pharmaceutical companies.
Chemical name: 17alpha-methyl-2-oxa-5alpha-androstan-17beta-ol-3-one
Molecular formula: C19H30O3
Molecular weight: 306.44 g/mol
Anabolic ratio: 322-630 vs testosterone baseline of 100
Androgenic ratio: 24 vs testosterone baseline of 100
Half-life: 9 to 10 hours
Bioavailability: 97% oral (one of the highest of any oral AAS)
Aromatization: None, there is no conversion to estrogen at any dose
5AR conversion: Does not convert to a more potent metabolite
FDA approval: Yes (Schedule III controlled substance)
Administration: Oral tablet (2.5 mg, 10 mg tablets commercially)
Manufacturer: Savient Pharmaceuticals, Hi-Tech Pharmaceuticals (Oxandrin brand)
Molecular formula: C19H30O3
Molecular weight: 306.44 g/mol
Anabolic ratio: 322-630 vs testosterone baseline of 100
Androgenic ratio: 24 vs testosterone baseline of 100
Half-life: 9 to 10 hours
Bioavailability: 97% oral (one of the highest of any oral AAS)
Aromatization: None, there is no conversion to estrogen at any dose
5AR conversion: Does not convert to a more potent metabolite
FDA approval: Yes (Schedule III controlled substance)
Administration: Oral tablet (2.5 mg, 10 mg tablets commercially)
Manufacturer: Savient Pharmaceuticals, Hi-Tech Pharmaceuticals (Oxandrin brand)
II. Structural Chemistry The 2-oxa Modification
Oxandrolone is a dihydrotestosterone (DHT) derivative modified at two positions.Understanding these modifications explains its unique pharmacological profile.
Modification 1: The 2-oxa substitution
In the standard steroid A-ring, position 2 carries a carbon atom. In oxandrolone, an oxygen atom replaces this carbon (hence "2-oxa"). This is the most structurally distinctive feature of the molecule.
Consequences of the 2-oxa substitution
Dramatically increases AR binding affinity (4-6x testosterone per HealthRx 2024)
Shifts the anabolic: androgenic selectivity toward muscle and away from prostate
makes the compound resistant to metabolic inactivation in muscle tissue
reduces interaction with 5-alpha reductase (already a DHT derivative)
Modification 2: The 2-oxa substitution
A methyl group at the 17-alpha position blocks first-pass hepatic metabolism. Without it, the liver would destroy the compound before it reaches circulation. This is what makes oxandrolone orally bioavailable at 97%. It is also what makes it hepatotoxic. See section 09 (IX)
Being a DHT derivative the key implication
DHT derivatives cannot be aromatised to estrogen. This is structural. The aromatase enzyme requires a specific A-ring configuration to convert the steroid. Both the DHT backbone and the 2-oxa modification prevent this. Result: zero estrogenic activity at any dose. No water retention. No gynecomastia from oxandrolone itself (though see HPTA section for context)
Oxandrolone is a dihydrotestosterone (DHT) derivative modified at two positions.Understanding these modifications explains its unique pharmacological profile.
Modification 1: The 2-oxa substitution
In the standard steroid A-ring, position 2 carries a carbon atom. In oxandrolone, an oxygen atom replaces this carbon (hence "2-oxa"). This is the most structurally distinctive feature of the molecule.
Consequences of the 2-oxa substitution
Dramatically increases AR binding affinity (4-6x testosterone per HealthRx 2024)
Shifts the anabolic: androgenic selectivity toward muscle and away from prostate
makes the compound resistant to metabolic inactivation in muscle tissue
reduces interaction with 5-alpha reductase (already a DHT derivative)
Modification 2: The 2-oxa substitution
A methyl group at the 17-alpha position blocks first-pass hepatic metabolism. Without it, the liver would destroy the compound before it reaches circulation. This is what makes oxandrolone orally bioavailable at 97%. It is also what makes it hepatotoxic. See section 09 (IX)
Being a DHT derivative the key implication
DHT derivatives cannot be aromatised to estrogen. This is structural. The aromatase enzyme requires a specific A-ring configuration to convert the steroid. Both the DHT backbone and the 2-oxa modification prevent this. Result: zero estrogenic activity at any dose. No water retention. No gynecomastia from oxandrolone itself (though see HPTA section for context)
III. Mechanism of Action AR Binding Genomic Effects IGF-1
Oxandrolone is a full agonist at the androgen receptor. This distinguishes it from SARMs which are partial agonists. Full agonism means complete coactivator recruitment and full genomic activation
AR Binding and Nuclear Translocation
Oxandrolone enters the cell via passive diffusion (lipophilic molecule)
Binds cytoplasmic androgen receptor with approximately 4-6x testosterone affinity (radiolabeled competitive binding assay data, HealthRx 2024)
AR undergoes conformational change. Coactivator proteins recruited
Oxandrolone-AR complex translocates to nucleus
Binds androgen response elements (AREs) on DNA
Activates transcription of androgen-responsive genes
Genes activated in muscle tissue
Nitrogen retention genes: Increased intramuscular nitrogen balance
Protein synthesis genes: Upregulation of ribosomal translation machinery
MyoD and myogenin: Myogenic regulatory factors driving muscle cell commitment
IGF-1 local expression: Intramuscular IGF-1 production elevated
Satellite cell activation: Muscle stem cells recruited to myofibers
Follistatin: Myostatin inhibitor, reduces muscle growth brake
SHBG reduction: Lower binding globulin increases free hormone fraction
The IGF-1 / mTOR / PI3K AXIS
AR activation drives local IGF-1 upregulation in muscle
IGF-1 binds IGF-1R on muscle cell surface
Activates PI3K / Akt / mTOR pathway
mTOR phosphorylates p70S6K and 4E-BP1
These activate ribosomal protein synthesis machinery. Net result: Accelerated muscle protein synthesis above baseline. mTOR also inhibits protein degradation via autophagy suppression. This IGF-1/mTOR axis is the primary anabolic amplification mechanismand is why oxandrolone's anabolic effect exceeds what AR binding alonewould predict based on dose.
Oxandrolone is a full agonist at the androgen receptor. This distinguishes it from SARMs which are partial agonists. Full agonism means complete coactivator recruitment and full genomic activation
AR Binding and Nuclear Translocation
Oxandrolone enters the cell via passive diffusion (lipophilic molecule)
Binds cytoplasmic androgen receptor with approximately 4-6x testosterone affinity (radiolabeled competitive binding assay data, HealthRx 2024)
AR undergoes conformational change. Coactivator proteins recruited
Oxandrolone-AR complex translocates to nucleus
Binds androgen response elements (AREs) on DNA
Activates transcription of androgen-responsive genes
Genes activated in muscle tissue
Nitrogen retention genes: Increased intramuscular nitrogen balance
Protein synthesis genes: Upregulation of ribosomal translation machinery
MyoD and myogenin: Myogenic regulatory factors driving muscle cell commitment
IGF-1 local expression: Intramuscular IGF-1 production elevated
Satellite cell activation: Muscle stem cells recruited to myofibers
Follistatin: Myostatin inhibitor, reduces muscle growth brake
SHBG reduction: Lower binding globulin increases free hormone fraction
The IGF-1 / mTOR / PI3K AXIS
AR activation drives local IGF-1 upregulation in muscle
IGF-1 binds IGF-1R on muscle cell surface
Activates PI3K / Akt / mTOR pathway
mTOR phosphorylates p70S6K and 4E-BP1
These activate ribosomal protein synthesis machinery. Net result: Accelerated muscle protein synthesis above baseline. mTOR also inhibits protein degradation via autophagy suppression. This IGF-1/mTOR axis is the primary anabolic amplification mechanismand is why oxandrolone's anabolic effect exceeds what AR binding alonewould predict based on dose.
IV. Glucocorticoid Receptor Antagonism The Anti-catabolic Mechanism
Oxandrolone's clinical utility in burns and HIV wasting is not only fromdriving anabolism. It also blocks the catabolic signal simultaneously. Cortisol binds glucocorticoid receptors (GR) in muscle tissue and drives: upregulation of muscle-specific ubiquitin ligases (MuRF1, MAFbx/atrogin-1) these E3 ligases tag muscle proteins for proteasomal degradationnet effect: muscle protein breakdown, atrophy, cachexia in catabolic states
Oxandrolone competes with cortisol at the glucocorticoid receptor (ResearchGate). This competition is androgen receptor-dependent (blocked by AR antagonists). AR and GR share structural homology and can cross-interact at receptor level.
The two-mechanism stack
Oxandrolone activates AR to drive protein synthesis
Oxandrolone blocks GR to reduce protein degradation
Both pathways active simultaneously
Net protein balance strongly positive during catabolic states
This is mechanistically identical to what makes trenbolone effective. The GC antagonism is why oxandrolone outperforms pure androgen replacementin clinical catabolic conditions beyond what the AR agonism alone would achieve.
Oxandrolone's clinical utility in burns and HIV wasting is not only fromdriving anabolism. It also blocks the catabolic signal simultaneously. Cortisol binds glucocorticoid receptors (GR) in muscle tissue and drives: upregulation of muscle-specific ubiquitin ligases (MuRF1, MAFbx/atrogin-1) these E3 ligases tag muscle proteins for proteasomal degradationnet effect: muscle protein breakdown, atrophy, cachexia in catabolic states
Oxandrolone competes with cortisol at the glucocorticoid receptor (ResearchGate). This competition is androgen receptor-dependent (blocked by AR antagonists). AR and GR share structural homology and can cross-interact at receptor level.
The two-mechanism stack
Oxandrolone activates AR to drive protein synthesis
Oxandrolone blocks GR to reduce protein degradation
Both pathways active simultaneously
Net protein balance strongly positive during catabolic states
This is mechanistically identical to what makes trenbolone effective. The GC antagonism is why oxandrolone outperforms pure androgen replacementin clinical catabolic conditions beyond what the AR agonism alone would achieve.
V. Muscle Effects Clinical Trial Data
Severe burns largest trial wolf et al. 2006
Wolf SE et al. (2006) Crit Care Med. Oxandrolone in severe burns RCT n=235
Adults with severe burns (>40% total body surface area).
Oxandrolone 20 mg/day for 6-12 months vs placebo.
Lean body mass preserved vs placebo group
Muscle strength significantly improved
Resting energy expenditure normalised faster
Hospital length of stay reduced
Wound healing rate improved
Paediatric burns Jeschke et al. 2012
Jeschke MG et al. (2012) Ann Surg. Paediatric burn oxandrolone: LBM, BMD, growth velocity
Children with burns >30% TBSA. Oxandrolone 0.1 mg/kg twice daily
Treatment duration: approximately 12 months post-burn
Mean hospital stay 26 days shorter than placebo
Lean body mass significantly improved at 12 months
Bone mineral content improved (see section 06 - VI) growth velocity maintained vs placebo decline
Safety profile confirmed in paediatric population
HIV wasting ORR and Singh 2004 Systematic Review
Orr R, Singh MF. (2004) Drugs. Oxandrolone in HIV wasting: systematic review
Review of multiple trials. Oxandrolone at 20-40 mg/day in HIV patients.
Weight gain confirmed across multiple trials
Lean body mass preservation confirmed
Quality of life improvements reported
Well tolerated at clinical doses in this population
ScienceDirect 2025 systematic review (24 studies, 1905 participants): Improvements in lean mass and muscle strength observed in older womenone of the few AAS with clinical trial data specifically in female populations
Nitrogen Retention
Nitrogen retention is the biochemical basis of muscle protein accretion
Positive nitrogen balance = more protein deposited than broken down
Oxandrolone produces strong positive nitrogen balance within days of initiation
This is confirmed across multiple clinical contexts
Severe burns largest trial wolf et al. 2006
Wolf SE et al. (2006) Crit Care Med. Oxandrolone in severe burns RCT n=235
Adults with severe burns (>40% total body surface area).
Oxandrolone 20 mg/day for 6-12 months vs placebo.
Lean body mass preserved vs placebo group
Muscle strength significantly improved
Resting energy expenditure normalised faster
Hospital length of stay reduced
Wound healing rate improved
Paediatric burns Jeschke et al. 2012
Jeschke MG et al. (2012) Ann Surg. Paediatric burn oxandrolone: LBM, BMD, growth velocity
Children with burns >30% TBSA. Oxandrolone 0.1 mg/kg twice daily
Treatment duration: approximately 12 months post-burn
Mean hospital stay 26 days shorter than placebo
Lean body mass significantly improved at 12 months
Bone mineral content improved (see section 06 - VI) growth velocity maintained vs placebo decline
Safety profile confirmed in paediatric population
HIV wasting ORR and Singh 2004 Systematic Review
Orr R, Singh MF. (2004) Drugs. Oxandrolone in HIV wasting: systematic review
Review of multiple trials. Oxandrolone at 20-40 mg/day in HIV patients.
Weight gain confirmed across multiple trials
Lean body mass preservation confirmed
Quality of life improvements reported
Well tolerated at clinical doses in this population
ScienceDirect 2025 systematic review (24 studies, 1905 participants): Improvements in lean mass and muscle strength observed in older womenone of the few AAS with clinical trial data specifically in female populations
Nitrogen Retention
Nitrogen retention is the biochemical basis of muscle protein accretion
Positive nitrogen balance = more protein deposited than broken down
Oxandrolone produces strong positive nitrogen balance within days of initiation
This is confirmed across multiple clinical contexts
VI. Bone effects BMD Osteoblast Stimulation Clinical Data
Oxandrolone has more clinical bone data than almost any other oral AAS. Three distinct mechanisms drive its bone effects
Clinical Bone Data
Burns bone mineral content Jeschke 2012
Paediatric burn patients on oxandrolone 0.1 mg/kg/day for ~12 months:whole body bone mineral content significantly improved vs placebo, lumbar BMD improve, deffect confirmed on both trabecular and cortical bone compartments.
Klinefelter syndrome cortical bone Hamwi 2021
Boys with Klinefelter syndrome have reduced cortical bone mass
Oxandrolone treatment: documented increase in cortical bone mass
Effect confirmed to be independent of estrogen (non-aromatizable compound)
AR-mediated effect on cortical bone confirmed
Turner syndrome bone and height
Ross JL et al. J Pediatr 2003: oxandrolone beneficial on final height
Menke LA Cochrane 2010: oxandrolone for GH-treated girls with Turner syndrome
Bone age velocity preserved without excessive advancement
Significant increase in growth velocity during oxandrolone periods
FDA-approved indication osteoporosis bone pain
Oxandrolone is FDA-approved for bone pain associated with osteoporosis. This makes it one of the very few AAS with a bone-specific clinical indication.
Oxandrolone has more clinical bone data than almost any other oral AAS. Three distinct mechanisms drive its bone effects
Kasperk CH et al. PMC1828036: oxandrolone directly stimulates osteoblastic cells
Specifically: stimulates collagen production in immature osteoblasts
Acts through the androgen receptor on osteoblast cell surfaces
Additional non-AR mechanisms also proposed (Kasperk 1997)
Net: more osteoblast activity = more bone matrix laid down = higher BMD
Specifically: stimulates collagen production in immature osteoblasts
Acts through the androgen receptor on osteoblast cell surfaces
Additional non-AR mechanisms also proposed (Kasperk 1997)
Net: more osteoblast activity = more bone matrix laid down = higher BMD
Cortisol excess is one of the primary drivers of bone loss
Glucocorticoid-induced osteoporosis (GIO) is the most commonform of secondary osteoporosis
Oxandrolone's GC antagonism protects bone from cortisol-driven resorptionin the same way it protects muscle
Particularly relevant in burn patientswhere cortisol is massively elevated for months post-injury
Glucocorticoid-induced osteoporosis (GIO) is the most commonform of secondary osteoporosis
Oxandrolone's GC antagonism protects bone from cortisol-driven resorptionin the same way it protects muscle
Particularly relevant in burn patientswhere cortisol is massively elevated for months post-injury
Local IGF-1 upregulation from AR activation also acts on osteoblasts
IGF-1 stimulates osteoblast proliferation and bone matrix synthesis
Oxandrolone in burns: demonstrated to preserve GH responsiveness in bone
IGF-1 stimulates osteoblast proliferation and bone matrix synthesis
Oxandrolone in burns: demonstrated to preserve GH responsiveness in bone
Burns bone mineral content Jeschke 2012
Paediatric burn patients on oxandrolone 0.1 mg/kg/day for ~12 months:whole body bone mineral content significantly improved vs placebo, lumbar BMD improve, deffect confirmed on both trabecular and cortical bone compartments.
Klinefelter syndrome cortical bone Hamwi 2021
Boys with Klinefelter syndrome have reduced cortical bone mass
Oxandrolone treatment: documented increase in cortical bone mass
Effect confirmed to be independent of estrogen (non-aromatizable compound)
AR-mediated effect on cortical bone confirmed
Turner syndrome bone and height
Ross JL et al. J Pediatr 2003: oxandrolone beneficial on final height
Menke LA Cochrane 2010: oxandrolone for GH-treated girls with Turner syndrome
Bone age velocity preserved without excessive advancement
Significant increase in growth velocity during oxandrolone periods
FDA-approved indication osteoporosis bone pain
Oxandrolone is FDA-approved for bone pain associated with osteoporosis. This makes it one of the very few AAS with a bone-specific clinical indication.
VII. FDA Approved Indications
Oxandrolone has more FDA-approved indications than any other oral AAS. This is why it has a far larger peer-reviewed evidence base than underground compounds.
Bone pain associated with osteoporosis
Weight recovery after surgery, severe trauma, or chronic infectionmuscle wasting in HIV/AIDS
Counteracting catabolic effects of long-term corticosteroid therapy
Severe burn injury recovery
Oxandrolone has more FDA-approved indications than any other oral AAS. This is why it has a far larger peer-reviewed evidence base than underground compounds.
Bone pain associated with osteoporosis
Weight recovery after surgery, severe trauma, or chronic infectionmuscle wasting in HIV/AIDS
Counteracting catabolic effects of long-term corticosteroid therapy
Severe burn injury recovery
Turner syndrome (growth velocity and final height)
Klinefelter syndrome (lean mass and bone)
Constitutional growth delay
Duchenne muscular dystrophy (limited data)
Alcoholic hepatitis (paradoxically, some positive data exists)
Spinal cord injury rehabilitation
Sarcopenia in elderly women
Klinefelter syndrome (lean mass and bone)
Constitutional growth delay
Duchenne muscular dystrophy (limited data)
Alcoholic hepatitis (paradoxically, some positive data exists)
Spinal cord injury rehabilitation
Sarcopenia in elderly women
VIII. Oral Bioavailability 17-Alpha Alkylation
When an oral steroid reaches the portal vein it is transported directlyto the liver before entering systemic circulation. The liver, as part ofits normal xenobiotic metabolism, would oxidise and inactivate most steroids before they could reach muscle or bone. This is first-pass metabolism.
The 17-alpha methyl group at the C-17 position sterically blocks the primarysite of hepatic metabolism (17-beta oxidation). The compound survives first pass essentially intact. Oral bioavailability: approximately 97%.This is why oxandrolone is effective orally at milligram-level doses.
The cost hepatic stress
The same resistance to hepatic metabolism that makes oral bioavailability possible also means the compound persists in hepatocytes for longer. Oxandrolone is processed more slowly by the liver than non-alkylated steroids. This prolonged hepatic exposure drives the hepatotoxicity. See section 09 (IX)
Half-life and dosing frequency
Half-life of oxandrolone: approximately 9-10 hours
Peak plasma concentration: approximately 1 hour post-dose
Clinical dosing: typically twice daily to maintain relatively stable plasma levels
FDA-approved clinical doses: 2.5-20 mg/day depending on indication and age
Paediatric burn studies: 0.1 mg/kg twice daily (Jeschke 2012)
HIV wasting studies: 20-40 mg/day (Orr and Singh 2004)
When an oral steroid reaches the portal vein it is transported directlyto the liver before entering systemic circulation. The liver, as part ofits normal xenobiotic metabolism, would oxidise and inactivate most steroids before they could reach muscle or bone. This is first-pass metabolism.
The 17-alpha methyl group at the C-17 position sterically blocks the primarysite of hepatic metabolism (17-beta oxidation). The compound survives first pass essentially intact. Oral bioavailability: approximately 97%.This is why oxandrolone is effective orally at milligram-level doses.
The cost hepatic stress
The same resistance to hepatic metabolism that makes oral bioavailability possible also means the compound persists in hepatocytes for longer. Oxandrolone is processed more slowly by the liver than non-alkylated steroids. This prolonged hepatic exposure drives the hepatotoxicity. See section 09 (IX)
Half-life and dosing frequency
Half-life of oxandrolone: approximately 9-10 hours
Peak plasma concentration: approximately 1 hour post-dose
Clinical dosing: typically twice daily to maintain relatively stable plasma levels
FDA-approved clinical doses: 2.5-20 mg/day depending on indication and age
Paediatric burn studies: 0.1 mg/kg twice daily (Jeschke 2012)
HIV wasting studies: 20-40 mg/day (Orr and Singh 2004)
IX. Hepatotoxicity The Liver Cost
All 17-alpha alkylated oral AAS cause hepatic stress. Oxandrolone is no exception. It is considered the least hepatotoxic 17-AA AAS, but hepatotoxicity is realand must be taken seriously.
What happens to the liver
ALT and AST elevation: both aminotransferases rise during oral AAS use
Mechanism: oxidative stress, lipid peroxidation, and direct steroid effectson hepatocyte metabolism (ScienceDirect 2025 systematic review)
Cholestatic hepatitis: bile flow obstruction. Documented in case reports
Peliosis hepatis: blood-filled cysts in liver parenchyma. Rare but documented
Hepatocellular carcinoma: documented with long-term high-dose 17-AA use
Oxandrolone at therapeutic doses: ALT/AST elevation typically mild and reversible
What makes Oxandrolone relatively less hepatotoxic
Lower absolute doses required due to high AR binding affinity
Clinical studies use 20-40 mg/day vs methyltestosterone at 200+ mg/day equivalents
Shorter recommended treatment durations in clinical use
ScienceDirect 2025: systematic review recommends monitoring but confirms
Hepatotoxicity is manageable with monitoring and dose adjustment
Monitoring
LFTs (ALT, AST, ALP, bilirubin) at baseline and every 4-6 weeks during use. If ALT or AST exceeds 3x upper limit of normal: dose reduction or discontinuation. Avoid concurrent alcohol use. Avoid other hepatotoxic drugs simultaneously.
All 17-alpha alkylated oral AAS cause hepatic stress. Oxandrolone is no exception. It is considered the least hepatotoxic 17-AA AAS, but hepatotoxicity is realand must be taken seriously.
What happens to the liver
ALT and AST elevation: both aminotransferases rise during oral AAS use
Mechanism: oxidative stress, lipid peroxidation, and direct steroid effectson hepatocyte metabolism (ScienceDirect 2025 systematic review)
Cholestatic hepatitis: bile flow obstruction. Documented in case reports
Peliosis hepatis: blood-filled cysts in liver parenchyma. Rare but documented
Hepatocellular carcinoma: documented with long-term high-dose 17-AA use
Oxandrolone at therapeutic doses: ALT/AST elevation typically mild and reversible
What makes Oxandrolone relatively less hepatotoxic
Lower absolute doses required due to high AR binding affinity
Clinical studies use 20-40 mg/day vs methyltestosterone at 200+ mg/day equivalents
Shorter recommended treatment durations in clinical use
ScienceDirect 2025: systematic review recommends monitoring but confirms
Hepatotoxicity is manageable with monitoring and dose adjustment
Monitoring
LFTs (ALT, AST, ALP, bilirubin) at baseline and every 4-6 weeks during use. If ALT or AST exceeds 3x upper limit of normal: dose reduction or discontinuation. Avoid concurrent alcohol use. Avoid other hepatotoxic drugs simultaneously.
X. Lipid effects HDL Suppression Cardiovascular
All AAS alter lipid metabolism. Oral 17-AA compounds are more lipotoxicthan injectable non-alkylated steroids due to first-pass hepatic effectson hepatic lipase and lipoprotein synthesis.
HDL Suppression
HDL (good cholesterol) is reduced by oral AAS use
Oxandrolone at clinical doses: HDL reduction of 25-50% from baseline
HDL is the primary reverse cholesterol transport mechanism
Lower HDL = reduced removal of LDL from arterial walls
Accelerated atherogenesis is the theoretical cardiovascular consequence
LDL Effects
LDL elevation is less consistent with oxandrolone than with methyltestosterone
Some studies show modest LDL increase. Others show neutral
The HDL suppression is the more consistent and concerning lipid finding
Cardiovascular Risk Assessment
Short-term clinical use (8-12 weeks) at approved doses: lipid changes are generally reversible upon discontinuation
Long-term use or high doses: cumulative atherogenic risk is real
Monitoring: fasting lipid panel at baseline and every 4-6 weeks
Fish oil supplementation reduces triglycerides and may partially offset HDL loss
All AAS alter lipid metabolism. Oral 17-AA compounds are more lipotoxicthan injectable non-alkylated steroids due to first-pass hepatic effectson hepatic lipase and lipoprotein synthesis.
HDL Suppression
HDL (good cholesterol) is reduced by oral AAS use
Oxandrolone at clinical doses: HDL reduction of 25-50% from baseline
HDL is the primary reverse cholesterol transport mechanism
Lower HDL = reduced removal of LDL from arterial walls
Accelerated atherogenesis is the theoretical cardiovascular consequence
LDL Effects
LDL elevation is less consistent with oxandrolone than with methyltestosterone
Some studies show modest LDL increase. Others show neutral
The HDL suppression is the more consistent and concerning lipid finding
Cardiovascular Risk Assessment
Short-term clinical use (8-12 weeks) at approved doses: lipid changes are generally reversible upon discontinuation
Long-term use or high doses: cumulative atherogenic risk is real
Monitoring: fasting lipid panel at baseline and every 4-6 weeks
Fish oil supplementation reduces triglycerides and may partially offset HDL loss
XI. HPTA Suppression How Significant For Oxandrolone
All exogenous androgens suppress the hypothalamic-pituitary-testicular axis (HPTA)
Elevated exogenous androgen signals the hypothalamus to reduce GnRH
Lower GnRH = lower LH = lower endogenous testosterone production
Oxandrolone vs Other AAS On HPTA Suppression
Oxandrolone is considered one of the least suppressive oral AAS
This is partly because it does not aromatize (no estrogen-mediated suppression)
And partly because lower doses are effective (less androgenic load on the axis)
At clinical doses (10-20 mg/day): partial HPTA suppression. LH reduced but not necessarily eliminated.
Endogenous testosterone reduces but not to zero
At higher doses or longer duration: suppression becomes more complete
---
In clinical burn and HIV studies where oxandrolone was used for 12+ months:
HPTA recovery after discontinuation was generally documented.
No permanent hypogonadism cases specifically attributed to oxandroloneat clinical doses in the peer-reviewed literature.
Women and HPTA
Women do not have the same HPTA concern re: testosterone
Primary concern in women: menstrual cycle disruption from AR activation
At low clinical doses oxandrolone is one of the few AAS used in femaleswithout high virilisation risk (see section 12-XII)
All exogenous androgens suppress the hypothalamic-pituitary-testicular axis (HPTA)
Elevated exogenous androgen signals the hypothalamus to reduce GnRH
Lower GnRH = lower LH = lower endogenous testosterone production
Oxandrolone vs Other AAS On HPTA Suppression
Oxandrolone is considered one of the least suppressive oral AAS
This is partly because it does not aromatize (no estrogen-mediated suppression)
And partly because lower doses are effective (less androgenic load on the axis)
At clinical doses (10-20 mg/day): partial HPTA suppression. LH reduced but not necessarily eliminated.
Endogenous testosterone reduces but not to zero
At higher doses or longer duration: suppression becomes more complete
---
In clinical burn and HIV studies where oxandrolone was used for 12+ months:
HPTA recovery after discontinuation was generally documented.
No permanent hypogonadism cases specifically attributed to oxandroloneat clinical doses in the peer-reviewed literature.
Women and HPTA
Women do not have the same HPTA concern re: testosterone
Primary concern in women: menstrual cycle disruption from AR activation
At low clinical doses oxandrolone is one of the few AAS used in femaleswithout high virilisation risk (see section 12-XII)
XII. Androgenic Side Effects Virilisation Hair Skin
Oxandrolone's androgenic ratio of 24 vs testosterone's 100 is the lowestof any commonly used AAS. This is the primary clinical reason it is usedin paediatric and female populations.
Why it is milder androgenically
The 2-oxa modification creates selective anabolic:androgenic separation. Oxandrolone is a DHT derivative: 5-alpha reductase does not convert itto a more potent metabolite in scalp or prostate tissue. The parent compound IS the most potent metabolite. No amplification. This is the same mechanism as trenbolone (see tren at section 13-XIII). Unlike trenbolone, the absolute AR potency is lower. So total androgenicload in androgen-sensitive tissues is meaningfully reduced.
Documented Androgenic Effects at Clinical Dose
Acne mild to moderate. dose-dependent
Hair loss only in genetically predisposed individuals, milder than testosterone
Virilisation in women voice deepening at higher doses. Cochrane 2010 noted this
As a reported adverse effect in Turner syndrome trials
Clitoral enlargement: documented at higher doses in females
Reporting was inadequate in some trials (Cochrane 2010)
Prostate effects less than testosterone. No significant prostate enlargement
Documented at clinical doses in existing literature
Compared to other oral AAS
Methyltestosterone highly androgenic. Severe HDL suppression. More hepatotoxic
Stanozolol moderate androgenic. Severe HDL suppression
Methandienone (dbol) aromatizes, water retention, moderate androgenic
Oxandrolone lowest androgenic ratio. Least virilising in women
Most clinical trial data, only one with multiple FDA indications
Oxandrolone's androgenic ratio of 24 vs testosterone's 100 is the lowestof any commonly used AAS. This is the primary clinical reason it is usedin paediatric and female populations.
Why it is milder androgenically
The 2-oxa modification creates selective anabolic:androgenic separation. Oxandrolone is a DHT derivative: 5-alpha reductase does not convert itto a more potent metabolite in scalp or prostate tissue. The parent compound IS the most potent metabolite. No amplification. This is the same mechanism as trenbolone (see tren at section 13-XIII). Unlike trenbolone, the absolute AR potency is lower. So total androgenicload in androgen-sensitive tissues is meaningfully reduced.
Documented Androgenic Effects at Clinical Dose
Acne mild to moderate. dose-dependent
Hair loss only in genetically predisposed individuals, milder than testosterone
Virilisation in women voice deepening at higher doses. Cochrane 2010 noted this
As a reported adverse effect in Turner syndrome trials
Clitoral enlargement: documented at higher doses in females
Reporting was inadequate in some trials (Cochrane 2010)
Prostate effects less than testosterone. No significant prostate enlargement
Documented at clinical doses in existing literature
Compared to other oral AAS
Methyltestosterone highly androgenic. Severe HDL suppression. More hepatotoxic
Stanozolol moderate androgenic. Severe HDL suppression
Methandienone (dbol) aromatizes, water retention, moderate androgenic
Oxandrolone lowest androgenic ratio. Least virilising in women
Most clinical trial data, only one with multiple FDA indications
XIII. Oxandrolone vs Other Oral AAS
Ratio 322-630 anabolic / 24 androgenic
Evidence multiple FDA approvals. 24 studies 1905 participants systematic review.
Burns, HIV, Turner, Klinefelter, elderly women.
Aromatization none
Hepatotoxicity mild to moderate. Least of 17-AA class
HDL suppression moderate 25-50%
HPTA suppression mild to moderate. least suppressive oral AAS
Virilization lowest of oral AAS class. used in children and women
Half-life 9 to10 hours. Twice daily dosing
Verdict A-TIER, best clinical evidence base of any oral AAS
Evidence multiple FDA approvals. 24 studies 1905 participants systematic review.
Burns, HIV, Turner, Klinefelter, elderly women.
Aromatization none
Hepatotoxicity mild to moderate. Least of 17-AA class
HDL suppression moderate 25-50%
HPTA suppression mild to moderate. least suppressive oral AAS
Virilization lowest of oral AAS class. used in children and women
Half-life 9 to10 hours. Twice daily dosing
Verdict A-TIER, best clinical evidence base of any oral AAS
Ratio 90-210 anabolic / 40-60 androgenic
Evidence limited clinical trial data. Used historically for aplastic anaemia and osteoporosis
Aromatization yes, significant. Water retention and gynecomastia risk
Hepatotoxicity moderate to severe
HDL suppression severe
HPTA suppression significant. suppresses rapidly
Virilization moderatehalf-life 3-6 hours. Multiple daily doses required
Verdict C-TIER pharmacologically vs oxandrolone, significant estrogen burden
Evidence limited clinical trial data. Used historically for aplastic anaemia and osteoporosis
Aromatization yes, significant. Water retention and gynecomastia risk
Hepatotoxicity moderate to severe
HDL suppression severe
HPTA suppression significant. suppresses rapidly
Virilization moderatehalf-life 3-6 hours. Multiple daily doses required
Verdict C-TIER pharmacologically vs oxandrolone, significant estrogen burden
Ratio 320 anabolic / 30 androgenic
Evidence limited human clinical data vs oxandrolone. Used in hereditary angioedema
Aromatization none. DHT derivative
Hepatotoxicity moderate. Comparable to oxandrolone
HDL suppression severe, worst of common oral AAS for HDL
HPTA suppression moderate
Virilization moderate. more than oxandrolone
Half-life 9 hours oral / 24 hours injectable
Verdict B-TIER. HDL suppression is significant limiting factor
Evidence limited human clinical data vs oxandrolone. Used in hereditary angioedema
Aromatization none. DHT derivative
Hepatotoxicity moderate. Comparable to oxandrolone
HDL suppression severe, worst of common oral AAS for HDL
HPTA suppression moderate
Virilization moderate. more than oxandrolone
Half-life 9 hours oral / 24 hours injectable
Verdict B-TIER. HDL suppression is significant limiting factor
Ratio 94-130 anabolic / 94-130 androgenic
Evidence oldest oral AAS. Still FDA-approved for hypogonadism, most studied historically
Aromatization yes, converts to methylestradiol (more potent than estradiol)
Hepatotoxicity most hepatotoxic common oral AAS
HDL suppression severe
HPTA suppression complete at clinical doses
Virilization high. equivalent to testosterone
Half-life 2.5-3.5 hours, multiple daily doses
Verdict D-TIER vs oxandrolone across every safety metric
Evidence oldest oral AAS. Still FDA-approved for hypogonadism, most studied historically
Aromatization yes, converts to methylestradiol (more potent than estradiol)
Hepatotoxicity most hepatotoxic common oral AAS
HDL suppression severe
HPTA suppression complete at clinical doses
Virilization high. equivalent to testosterone
Half-life 2.5-3.5 hours, multiple daily doses
Verdict D-TIER vs oxandrolone across every safety metric
XIV. Legal Status and Scheduling
United States Schedule III controlled substance (CSA)
Prescription required. FDA-approved Oxandrin available
United Kingdom Class C controlled drug under Misuse of Drugs Act 1971
Australia Schedule 4 prescription medicine
Canada Schedule IV controlled drug
WADA Prohibited in all sports in and out of competition
Unlike most oral AAS, pharmaceutical-grade oxandrolone is still legallymanufactured and available by prescription in many countries. Oxandrin (BTG/Savient) is available in the US by prescription. Generic oxandrolone tablets are manufactured by multiple companies. This means pharmaceutical-grade product with verified purity and dosageis obtainable through legitimate medical channels, unlike most AAS.
United States Schedule III controlled substance (CSA)
Prescription required. FDA-approved Oxandrin available
United Kingdom Class C controlled drug under Misuse of Drugs Act 1971
Australia Schedule 4 prescription medicine
Canada Schedule IV controlled drug
WADA Prohibited in all sports in and out of competition
Unlike most oral AAS, pharmaceutical-grade oxandrolone is still legallymanufactured and available by prescription in many countries. Oxandrin (BTG/Savient) is available in the US by prescription. Generic oxandrolone tablets are manufactured by multiple companies. This means pharmaceutical-grade product with verified purity and dosageis obtainable through legitimate medical channels, unlike most AAS.
XV. Verdict
WHAT OXANDROLONE IS
The most clinically studied oral anabolic steroid in existence
The only oral AAS with multiple distinct FDA-approved indications
A 2-oxa modified DHT derivative with genuinely selective anabolic:androgenic ratio
Confirmed mechanisms for both muscle protein accretion and bone formation
24 studies with 1905 participants in systematic review. Burns, HIV, Klinefelter
Turner syndrome. Elderly women. Spinal cord injury. The evidence base is real
STRENGTHS
Lowest androgenic ratio of common oral AAS
No aromatization. No estrogen-related side effects from oxandrolone itself
97% oral bioavailability at relatively low absolute doses
Dual anabolic + anti-catabolic mechanism (AR agonism + GC antagonism)
Direct osteoblast stimulation confirmed in cell culture
Bone mineral content improvements in clinical trials
Pharmaceutical-grade product available through legitimate prescription channels
Used safely in children and women in peer-reviewed clinical trials
LIMITATIONS AND RISKS
Hepatotoxic: 17-AA structure. ALT/AST monitoring mandatory
HDL suppression: 25-50% reduction. cardiovascular risk accumulates with duration
HPTA suppression: real, though milder than most AAS
Schedule III controlled substance: prescription required in most countries
Virilisation in women at higher doses: documented. voice, clitoral effects
Hair loss in genetically predisposed individuals
A-TIER oral AAS by clinical evidence and safety profilebest pharmacological ratio in the oral AAS class
WHAT OXANDROLONE IS
The most clinically studied oral anabolic steroid in existence
The only oral AAS with multiple distinct FDA-approved indications
A 2-oxa modified DHT derivative with genuinely selective anabolic:androgenic ratio
Confirmed mechanisms for both muscle protein accretion and bone formation
24 studies with 1905 participants in systematic review. Burns, HIV, Klinefelter
Turner syndrome. Elderly women. Spinal cord injury. The evidence base is real
STRENGTHS
Lowest androgenic ratio of common oral AAS
No aromatization. No estrogen-related side effects from oxandrolone itself
97% oral bioavailability at relatively low absolute doses
Dual anabolic + anti-catabolic mechanism (AR agonism + GC antagonism)
Direct osteoblast stimulation confirmed in cell culture
Bone mineral content improvements in clinical trials
Pharmaceutical-grade product available through legitimate prescription channels
Used safely in children and women in peer-reviewed clinical trials
LIMITATIONS AND RISKS
Hepatotoxic: 17-AA structure. ALT/AST monitoring mandatory
HDL suppression: 25-50% reduction. cardiovascular risk accumulates with duration
HPTA suppression: real, though milder than most AAS
Schedule III controlled substance: prescription required in most countries
Virilisation in women at higher doses: documented. voice, clitoral effects
Hair loss in genetically predisposed individuals
A-TIER oral AAS by clinical evidence and safety profilebest pharmacological ratio in the oral AAS class
@TonyDr @rand anon @giga.mia @True Spaniard @Luffy @Aryy @plasty @zennn @whore @copevictim @Lmtnboy1748 @MasterOfTheZygo @rcamg @yyoloo @klyro @dontcallthemfoidsbro @limo8 @Nobodyreallycares @Improvedlook @makoto @DEAN 2.0 @Yeat @Dearpleasehelpme @Br4va @Recai @foidslayer @northka @sub8 warrior @xorsizm @thushebecame @rxpeangelz @sodium @kittycorn3 @chels_slayer @Neurodivergentt @XWJJ @TFC @charvapilled @Mr. Oxytocin @Tealovingfool @junebug @Suomi Volksgrenadier
